{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:09:33Z","timestamp":1784038173102,"version":"3.55.0"},"reference-count":48,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,14]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Cutaneous T-cell lymphoma (CTCL) is a heterogeneous non-Hodgkin hematolymphoid malignancy characterized by clonal T-cell receptors (TCRs), which serve as diagnostic hallmarks and potential therapeutic targets. Advanced CTCL remains difficult to treat, with poor prognosis and heterogeneous expression of actionable treatment targets across cancer subclones; however, all express the same clonal TCR. Antibodies against the TCR constant \u03b2-chain region can eliminate cancer T cells but may also deplete approximately half of benign T cells. In contrast, each TCR variable \u03b2-chain (TRBV or TCRV\u03b2) family is expressed by only a small percentage (1%-10%) of normal T cells, making it an attractive clone-restricted target. Analysis of TCR sequencing from 104 patients with CTCL showed TCR V\u03b22 (TRBV20-1) is the most common form of TCRV\u03b2. Here, we demonstrate that an anti-TCR V\u03b22 antibody is efficiently internalized and traffics to lysosomes, fulfilling key requirements for antibody-drug conjugate (ADC) development. A TCR V\u03b22-directed ADC selectively kills the TCR V\u03b22+ malignant MOLT-16 T-cell line and primary TCRV\u03b22+ cancer T cells from patients with leukemic CTCL (n = 6; 4 with TCRV\u03b22+ and 2 with TCR V\u03b22\u2212), whereas the unconjugated antibody has little effect. In a MOLT-16 tumor mouse model, TCR V\u03b22 ADC significantly inhibits tumor growth. In conclusion, TCRV\u03b2-specific ADC is a novel, clone-targeted strategy to eliminate cancer T cells by exploiting their clonal TCR while minimizing collateral damage to the healthy T-cell repertoire.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020282","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:54:53Z","timestamp":1777488893000},"page":"4508-4516","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["TCRV\u03b2-targeting antibody-drug conjugates as a novel strategy to eliminate malignant T cells in T cell cancers"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3710-5143","authenticated-orcid":false,"given":"Chella Krishna","family":"Vadivel","sequence":"first","affiliation":[{"name":"1LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1299-0991","authenticated-orcid":false,"given":"Kirstine Sandal","family":"N\u00f8rregaard","sequence":"additional","affiliation":[{"name":"2The Finsen Laboratory, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark"},{"name":"3Biotech Research & Innovation Centre, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3783-8288","authenticated-orcid":false,"given":"Alba Mart\u00ednez","family":"Perlado","sequence":"additional","affiliation":[{"name":"2The Finsen Laboratory, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark"},{"name":"3Biotech Research & Innovation Centre, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3157-7115","authenticated-orcid":false,"given":"Lara P.","family":"Sorrosal","sequence":"additional","affiliation":[{"name":"1LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9138-602X","authenticated-orcid":false,"given":"Ziao","family":"Zeng","sequence":"additional","affiliation":[{"name":"1LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6336-723X","authenticated-orcid":false,"given":"Lang","family":"Yan","sequence":"additional","affiliation":[{"name":"1LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7526-7883","authenticated-orcid":false,"given":"Martin R.J.","family":"Namini","sequence":"additional","affiliation":[{"name":"1LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gluud","sequence":"additional","affiliation":[{"name":"1LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7180-6384","authenticated-orcid":false,"given":"Terkild B.","family":"Buus","sequence":"additional","affiliation":[{"name":"1LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars H.","family":"Engelholm","sequence":"additional","affiliation":[{"name":"2The Finsen Laboratory, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark"},{"name":"3Biotech Research & Innovation Centre, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1833-3922","authenticated-orcid":false,"given":"Niels","family":"Behrendt","sequence":"additional","affiliation":[{"name":"2The Finsen Laboratory, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark"},{"name":"3Biotech Research & Innovation Centre, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3135-5624","authenticated-orcid":false,"given":"Niels","family":"\u00d8dum","sequence":"additional","affiliation":[{"name":"1LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"issue":"1","key":"2026071409572212600_bib1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-021-00296-9","article-title":"Cutaneous T cell lymphoma","volume":"7","author":"Dummer","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"19","key":"2026071409572212600_bib2","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1056\/NEJMra032810","article-title":"The pathogenesis of mycosis fungoides","volume":"350","author":"Girardi","year":"2004","journal-title":"N Engl J Med"},{"issue":"10","key":"2026071409572212600_bib3","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1001\/jama.1992.03480100060031","article-title":"Infections complicating mycosis fungoides and Sezary syndrome","volume":"267","author":"Axelrod","year":"1992","journal-title":"JAMA"},{"issue":"10","key":"2026071409572212600_bib4","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1158\/2159-8290.CD-24-1856","article-title":"Divergent evolution of malignant subclones maintains a balance between induced aggressiveness and intrinsic drug resistance in T-cell cancer","volume":"15","author":"Buus","year":"2025","journal-title":"Cancer Discov"},{"issue":"12","key":"2026071409572212600_bib5","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/cup.12797","article-title":"Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding","volume":"43","author":"Al-Rohil","year":"2016","journal-title":"J Cutan Pathol"},{"issue":"829","key":"2026071409572212600_bib6","doi-asserted-by":"crossref","first-page":"eady4877","DOI":"10.1126\/scitranslmed.ady4877","article-title":"Single-amino acid variants in target epitopes can confer resistance to antibody-based therapies","volume":"17","author":"Marone","year":"2025","journal-title":"Sci Transl Med"},{"issue":"308","key":"2026071409572212600_bib7","doi-asserted-by":"crossref","first-page":"308ra158","DOI":"10.1126\/scitranslmed.aaa9122","article-title":"TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL","volume":"7","author":"Kirsch","year":"2015","journal-title":"Sci Transl Med"},{"issue":"2","key":"2026071409572212600_bib8","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/modpathol.2009.175","article-title":"Flow cytometric detection of peripheral blood involvement by mycosis fungoides and Sezary syndrome using T-cell receptor Vbeta chain antibodies and its application in blood staging","volume":"23","author":"Feng","year":"2010","journal-title":"Mod Pathol"},{"issue":"1","key":"2026071409572212600_bib9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41591-024-03326-7","article-title":"TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1\/2 trial","volume":"31","author":"Cwynarski","year":"2025","journal-title":"Nat Med"},{"issue":"12","key":"2026071409572212600_bib10","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/nm.4444","article-title":"Targeting the T cell receptor \u03b2-chain constant region for immunotherapy of T cell malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat Med"},{"issue":"12","key":"2026071409572212600_bib11","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1038\/s43018-025-01069-z","article-title":"TRBC2-targeting antibody\u2013drug conjugates for the treatment of T cell cancers","volume":"6","author":"Ge","year":"2025","journal-title":"Nat Cancer"},{"issue":"1","key":"2026071409572212600_bib12","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41467-024-44786-2","article-title":"Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-V\u03b22+ T cell malignancy","volume":"15","author":"Ren","year":"2024","journal-title":"Nat Commun"},{"issue":"8007","key":"2026071409572212600_bib13","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/s41586-024-07233-2","article-title":"TRBC1-targeting antibody-drug conjugates for the treatment of T cell cancers","volume":"628","author":"Nichakawade","year":"2024","journal-title":"Nature"},{"issue":"9","key":"2026071409572212600_bib14","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1182\/bloodadvances.2022008798","article-title":"TCRv\u03b2-CART therapy mediates high-precision targeting of malignant T-cell clones","volume":"7","author":"Shaw","year":"2023","journal-title":"Blood Adv"},{"issue":"584","key":"2026071409572212600_bib15","doi-asserted-by":"crossref","first-page":"eabd3595","DOI":"10.1126\/scitranslmed.abd3595","article-title":"TCR \u03b2 chain-directed bispecific antibodies for the treatment of T cell cancers","volume":"13","author":"Paul","year":"2021","journal-title":"Sci Transl Med"},{"issue":"4","key":"2026071409572212600_bib16","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/1097-0320(20000801)40:4<336::AID-CYTO9>3.0.CO;2-0","article-title":"Flow cytometric analysis of the Vbeta repertoire in healthy controls","volume":"40","author":"van den Beemd","year":"2000","journal-title":"Cytometry"},{"issue":"11","key":"2026071409572212600_bib17","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","article-title":"The journey of antibody-drug conjugates: lessons learned from 40 years of development","volume":"14","author":"Colombo","year":"2024","journal-title":"Cancer Discov"},{"issue":"3","key":"2026071409572212600_bib18","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"2026071409572212600_bib19","doi-asserted-by":"crossref","first-page":"102684","DOI":"10.1016\/j.eclinm.2024.102684","article-title":"Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase","volume":"73","author":"Shen","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"15","key":"2026071409572212600_bib20","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1182\/blood.2023021671","article-title":"Staphylococcus aureus induces drug resistance in cancer T cells in S\u00e9zary syndrome","volume":"143","author":"Vadivel","year":"2024","journal-title":"Blood"},{"issue":"8","key":"2026071409572212600_bib21","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood-2006-04-017863","article-title":"Nonmalignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxins","volume":"109","author":"Woetmann","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2026071409572212600_bib22","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3390\/cancers13020280","article-title":"JAK3 Is expressed in the nucleus of malignant T cells in cutaneous T cell lymphoma (CTCL)","volume":"13","author":"Vadivel","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"2026071409572212600_bib23","doi-asserted-by":"crossref","first-page":"eadq0513","DOI":"10.1126\/sciadv.adq0513","article-title":"Targeting uPAR with an antibody-drug conjugate suppresses tumor growth and reshapes the immune landscape in pancreatic cancer models","volume":"11","author":"Metrangolo","year":"2025","journal-title":"Sci Adv"},{"key":"2026071409572212600_bib24","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/978-1-62703-541-5_16","article-title":"Drug-to-antibody ratio (DAR) by UV\/Vis spectroscopy","volume":"1045","author":"Chen","year":"2013","journal-title":"Methods Mol Biol"},{"issue":"2","key":"2026071409572212600_bib25","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jaci.2024.09.004","article-title":"Single-cell sequencing delineates T-cell clonality and pathogenesis of the parapsoriasis disease group","volume":"155","author":"Alkon","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"2026071409572212600_bib26","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/bloodadvances.2021005991","article-title":"Single-cell analysis of Sezary syndrome reveals novel markers and shifting gene profiles associated with treatment","volume":"7","author":"Borcherding","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"2026071409572212600_bib27","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.jaci.2024.11.037","article-title":"Single-cell RNA sequencing of chronic idiopathic erythroderma defines disease-specific markers","volume":"155","author":"Chennareddy","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"2026071409572212600_bib28","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/bjd\/ljae313","article-title":"Single-cell RNA sequencing comparison of CD4+, CD8+ and T-cell receptor gammadelta+ cutaneous T-cell lymphomas reveals subset-specific molecular phenotypes","volume":"192","author":"Chennareddy","year":"2025","journal-title":"Br J Dermatol"},{"issue":"12","key":"2026071409572212600_bib29","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1158\/1078-0432.CCR-21-4437","article-title":"Single-cell RNA sequencing unveils the clonal and transcriptional landscape of cutaneous T-cell lymphomas","volume":"28","author":"Gaydosik","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"18","key":"2026071409572212600_bib30","doi-asserted-by":"crossref","first-page":"5586","DOI":"10.1182\/bloodadvances.2022008562","article-title":"Sezary syndrome originates from heavily mutated hematopoietic progenitors","volume":"7","author":"Harro","year":"2023","journal-title":"Blood Adv"},{"issue":"16","key":"2026071409572212600_bib31","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1182\/blood.2020009346","article-title":"Multimodal single-cell analysis of cutaneous T-cell lymphoma reveals distinct subclonal tissue-dependent signatures","volume":"138","author":"Herrera","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2026071409572212600_bib32","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1038\/s41590-024-02018-1","article-title":"Cutaneous T cell lymphoma atlas reveals malignant T(H)2 cells supported by a B cell-rich tumor microenvironment","volume":"25","author":"Li","year":"2024","journal-title":"Nat Immunol"},{"issue":"1","key":"2026071409572212600_bib33","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/s41467-022-28799-3","article-title":"Single-cell transcriptomics links malignant T cells to the tumor immune landscape in cutaneous T cell lymphoma","volume":"13","author":"Liu","year":"2022","journal-title":"Nat Commun"},{"key":"2026071409572212600_bib34","doi-asserted-by":"crossref","first-page":"1090592","DOI":"10.3389\/fonc.2023.1090592","article-title":"Phenotypic plasticity of malignant T cells in blood and skin of a Sezary syndrome patient revealed by single cell transcriptomics","volume":"13","author":"Peiffer","year":"2023","journal-title":"Front Oncol"},{"issue":"3","key":"2026071409572212600_bib35","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/bloodadvances.2022008168","article-title":"Integrated transcriptome and trajectory analysis of cutaneous T-cell lymphoma identifies putative precancer populations","volume":"7","author":"Ren","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2026071409572212600_bib36","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12943-021-01419-2","article-title":"Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma","volume":"20","author":"Rindler","year":"2021","journal-title":"Mol Cancer"},{"issue":"5","key":"2026071409572212600_bib37","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1158\/2159-8290.CD-21-1207","article-title":"Genomic and single-cell landscape reveals novel drivers and therapeutic vulnerabilities of transformed cutaneous T-cell lymphoma","volume":"12","author":"Song","year":"2022","journal-title":"Cancer Discov"},{"issue":"24","key":"2026071409572212600_bib38","doi-asserted-by":"crossref","first-page":"127640","DOI":"10.1016\/j.bmcl.2020.127640","article-title":"Evaluation of PNU-159682 antibody drug conjugates (ADCs)","volume":"30","author":"Holte","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"2026071409572212600_bib39","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1158\/0008-5472.CAN-25-0881","article-title":"Multiomics profiling of T-cell leukemia and lymphoma enables targeted therapeutic discovery","volume":"86","author":"Ianevski","year":"2026","journal-title":"Cancer Res"},{"issue":"56","key":"2026071409572212600_bib40","doi-asserted-by":"crossref","first-page":"95981","DOI":"10.18632\/oncotarget.21619","article-title":"Analysis of CTCL cell lines reveals important differences between mycosis fungoides\/Sezary syndrome vs. HTLV-1(+) leukemic cell lines","volume":"8","author":"Netchiporouk","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"2026071409572212600_bib41","doi-asserted-by":"crossref","first-page":"11301","DOI":"10.1038\/s41598-017-11310-0","article-title":"Assessment of T-cell receptor repertoire and clonal expansion in peripheral T-cell lymphoma using RNA-seq data","volume":"7","author":"Gong","year":"2017","journal-title":"Sci Rep"},{"issue":"8","key":"2026071409572212600_bib42","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JOP.2017.021907","article-title":"Adult T-cell leukemia\/lymphoma","volume":"13","author":"Mehta-Shah","year":"2017","journal-title":"J Oncol Pract"},{"issue":"7","key":"2026071409572212600_bib43","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1182\/bloodadvances.2021005884","article-title":"Clonotype pattern in T-cell lymphomas map the cell of origin to immature lymphoid precursors","volume":"6","author":"Iyer","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2026071409572212600_bib44","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-024-01002-0","article-title":"Dual T-cell constant \u03b2 chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry","volume":"14","author":"Horna","year":"2024","journal-title":"Blood Cancer J"},{"issue":"1","key":"2026071409572212600_bib45","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1001\/jamadermatol.2025.4081","article-title":"T-cell receptor clonotypes and aggressive subtypes in cutaneous T-cell lymphoma","volume":"162","author":"Crisan","year":"2026","journal-title":"JAMA Dermatol"},{"issue":"11","key":"2026071409572212600_bib46","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1038\/s41591-023-02613-z","article-title":"Targeted depletion of TRBV9(+) T cells as immunotherapy in a patient with ankylosing spondylitis","volume":"29","author":"Britanova","year":"2023","journal-title":"Nat Med"},{"issue":"7","key":"2026071409572212600_bib47","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.3390\/pharmaceutics13071040","article-title":"mRNA-based anti-TCR CDR3 tumour vaccine for T-cell lymphoma","volume":"13","author":"Tusup","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1","key":"2026071409572212600_bib48","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12943-025-02489-2","article-title":"Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions","volume":"24","author":"Chen","year":"2025","journal-title":"Mol Cancer"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/13\/4508\/2530097\/blooda_adv-2026-020282-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/13\/4508\/2530097\/blooda_adv-2026-020282-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:57:35Z","timestamp":1784037455000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/13\/4508\/568093\/TCRV-targeting-antibody-drug-conjugates-as-a-novel"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":48,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,7,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020282","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,14]]},"published":{"date-parts":[[2026,6,25]]}}}